IN Insider Trading

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): C$15,965.89
Insider Selling (Last 12 Months): C$0.00

InMed Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at InMed Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

InMed Pharmaceuticals Share Price & Price History

Current Price: C$0.00
Price Change: +0.30 (1.20%)
As of 05/7/2021 01:00 AM ET

This chart shows the closing price history over time for IN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

InMed Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/13/2022Eric Ashley AdamsDirectorBuy8,560C$1.07C$9,167.7644,843
1/24/2022Bruce ColwillSenior OfficerBuy5,000C$1.36C$6,798.1311,515
9/28/2021Eric Ashley AdamsDirectorBuy11,400C$2.31C$26,379.1427,483
11/28/2019Eric Ashley AdamsDirectorBuy100,000C$0.25C$25,000.00530,725
10/31/2019Alexandra Diane Janet ManciniSenior OfficerBuy8,500C$0.25C$2,097.80166,500
10/28/2019Alexandra Diane Janet ManciniSenior OfficerBuy10,000C$0.26C$2,600.00158,000
10/24/2019Alexandra Diane Janet ManciniSenior OfficerBuy1,500C$0.26C$390.00148,000
10/21/2019Alexandra Diane Janet ManciniSenior OfficerBuy2,500C$0.27C$675.00136,500
10/17/2019Alexandra Diane Janet ManciniSenior OfficerBuy14,000C$0.27C$3,710.00134,000
10/15/2019Alexandra Diane Janet ManciniSenior OfficerBuy10,000C$0.28C$2,800.00110,000
10/11/2019Alexandra Diane Janet ManciniSenior OfficerBuy15,000C$0.26C$3,825.00100,000
See Full Table

SEC Filings (Institutional Ownership Changes) for InMed Pharmaceuticals (TSE:IN)

InMed Pharmaceuticals logo
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Read More on InMed Pharmaceuticals

Today's Range

Now: N/A

50 Day Range

MA: C$4.19
Low: C$4.19
High: C$4.19

52 Week Range

Now: N/A

Volume

17,035 shs

Average Volume

29,552 shs

Market Capitalization

C$33.73 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of InMed Pharmaceuticals?

InMed Pharmaceuticals' top insider shareholders include:
  1. Eric Ashley Adams (Director)
  2. Bruce Colwill (Senior Officer)
Learn More about top insider investors at InMed Pharmaceuticals.
Next-Generation Fighter Jets?!? (Must See)
The U.S. Department of Defense is using one shocking company to develop breakthrough tech...And at less than $2... this could be the last bargain on the market.

Get the Details Here (Act Fast... a Key Announcement in December Could Send It Rocketing)
>>>
pixel